HitGen Inc

HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and...

Hit identification,lead generation,chemical library synthesis,early phase r&d,protein production and purification,dna encoded libraries,hit expansion libraries,screening libraries,drug discovery,synthetic therapeutic oligonucleotide, fragment-based drug discovery, structure-based drug design,e3 ligases,targeted protein degradation ,and new molecular entities

Hitgen inc operates in the Biotechnology research industry.

Hitgen inc's revenue is 11m - 100m

Hitgen inc has 51 - 200 employees.